Log in

Relevant bibliographies by topics / Vaccine development / Journal articles

To see the other types of publications on this topic, follow the link: Vaccine development.

Journal articles on the topic 'Vaccine development'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Vaccine development.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Alexander, NJ, and G. Bialy. "Contraceptive vaccine development." Reproduction, Fertility and Development 6, no. 3 (1994): 273. http://dx.doi.org/10.1071/rd9940273.

Full text

Abstract:

Recent advances in antigen definition and production have made the development of a contraceptive vaccine more attainable. Such a vaccine must evoke an immune response that blocks an indispensable step in the reproductive process. Vaccine research involves many approaches to fertility prevention. Vaccines are being developed that could interrupt fertility by inhibition of gonadotrophin release, the function of follicle-stimulating hormone or the effects of human chorionic gonadotrophin (hCG); alternatively, they may prevent fertilization by interfering with the transport of spermatozoa or with

APA, Harvard, Vancouver, ISO, and other styles

2

Mastroeni,, Pietro, and Nathalie Ménager. "Development of acquired immunity to Salmonella." Journal of Medical Microbiology 52, no. 6 (2003): 453–59. http://dx.doi.org/10.1099/jmm.0.05173-0.

Full text

Abstract:

Salmonella enterica serovar Typhi (S. typhi) causes human typhoid fever, a serious and widespread disease in developing countries. Other Salmonella serovars are associated with food-borne infections. The recent emergence of multi-drug-resistant Salmonella strains highlights the need for better preventive measures, including vaccination. The available vaccines against Salmonella infection do not confer optimal protection. The design of new Salmonella vaccines must be based on the identification of suitable virulence genes and on knowledge of the immunological mechanisms of resistance to the dis

APA, Harvard, Vancouver, ISO, and other styles

3

Xia, Yueting. "New Development of Vaccine Technology in Tumor Therapy." Theoretical and Natural Science 59, no. 1 (2024): 269–76. http://dx.doi.org/10.54254/2753-8818/59/20241442.

Full text

Abstract:

Abstract. Cancer vaccines are a crucial component of tumors immunotherapy, offering the advantage of minimizing adverse reactions to induce tumor regression. They also enable the establishment of lasting anti-tumor memory. Recent years have seen significant breakthroughs in cancer vaccines, including the customization of personalized vaccines and the transition from passive immunization to active treatment. Currently, most cancer vaccine future goals focus on improving cost and efficiency such as combining immunology and bioinformatics to predict more accurate vaccine epitopes. This paper focu

APA, Harvard, Vancouver, ISO, and other styles

4

Deng, Sheng-Qun, Xian Yang, Yong Wei, Jia-Ting Chen, Xiao-Jun Wang, and Hong-Juan Peng. "A Review on Dengue Vaccine Development." Vaccines 8, no. 1 (2020): 63. http://dx.doi.org/10.3390/vaccines8010063.

Full text

Abstract:

Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D—tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in

APA, Harvard, Vancouver, ISO, and other styles

5

Titanji, Vincent P. K. "New approaches to vaccines for endemic and pandemic diseases of Africa with particular focus on building local competencies in Cameroon." Journal of the Cameroon Academy of Sciences 17, no. 1 (2021): 75–83. http://dx.doi.org/10.4314/jcas.v17i1.6.

Full text

Abstract:

Vaccines have been recognized as major and effective tools for the control and eventual elimination of infectious diseases and cancer. This brief review examines vaccine classification and development pipeline as well as recent innovations driving the vaccine development process. Using COVID-19 as an example recent innovation in vaccine development are highlighted. The review ends with a call for intensified efforts to build vaccine production capacity in Cameroon and other other African countries. Les vaccins ont été reconnus comme des outils majeurs et efficaces pour le contrôle et l’é

APA, Harvard, Vancouver, ISO, and other styles

6

Aljohani, Salwa, Waleed M. Hussein, Istvan Toth, and Pavla Simerska. "Carbohydrates in Vaccine Development." Current Drug Delivery 16, no. 7 (2019): 609–17. http://dx.doi.org/10.2174/1567201816666190702153612.

Full text

Abstract:

Despite advances in the development of new vaccines, there are still some diseases with no vaccine solutions. Therefore, further efforts are required to more comprehensively discern the different antigenic components of these microorganisms on a molecular level. This review summarizes advancement in the development of new carbohydrate-based vaccines. Following traditional vaccine counterparts, the carbohydrate-based vaccines introduced a new approach in fighting infectious diseases. Carbohydrates have played various roles in the development of carbohydrate-based vaccines, which are described i

APA, Harvard, Vancouver, ISO, and other styles

7

AM, Aga. "Recent Advances in mRNA Vaccine Development." Open Access Journal of Microbiology & Biotechnology 8, no. 4 (2023): 1–17. http://dx.doi.org/10.23880/oajmb-16000275.

Full text

Abstract:

Messenger RNA vaccines are vaccine that utilizes a small segment of genetic material, messenger RNA (mRNA), to provide instructions to cells to produce a specific protein. This mRNA is synthesized in a laboratory and packaged into lipid nanoparticles, which protect and facilitate its entry into cells for protein synthesis. Upon injection into the muscle of the recipient, the mRNA instructs cells to produce a protein that is displayed on the surface of the cell, triggering an immune response. The immune system then produces antibodies and activates immune cells to target and eliminate the prote

APA, Harvard, Vancouver, ISO, and other styles

8

Suo, Zhaotaize. "Universal Vaccine Development Against COVID-19 and Influenza." E3S Web of Conferences 553 (2024): 05044. http://dx.doi.org/10.1051/e3sconf/202455305044.

Full text

Abstract:

Universal vaccines appeared as a favorable solution for the rapid mutation of viruses that cause pandemics. Sufficient immune protection, safe and efficient production methods, and low-cost funding are ideal properties for universal vaccines. Targeting conserved regions, use of adjuvants, cell-mediated immunity approaches, virus-like particles, and multimeric presentation of viral antigens are strategies to enhance vaccine Immunogenicity. Different types of vaccines have been put into clinical trials, such as messenger RNA vaccines, on-replicating viral vector vaccines, and recombinant protein

APA, Harvard, Vancouver, ISO, and other styles

9

Mboup, Elhadji Birane, Marie-Ève Hamelin, Julia Dubois, Manuel Rosa-Calatrava, and Guy Boivin. "Vaccine Development for Human Pneumoviruses." Vaccines 13, no. 6 (2025): 569. https://doi.org/10.3390/vaccines13060569.

Full text

Abstract:

Background: Pneumoviruses are etiologic agents of respiratory tract infections and a major cause of morbidity and mortality worldwide, particularly affecting young children, the elderly, and individuals with underlying clinical conditions. These viruses are associated with a significant burden, particularly in low- and middle-income countries, where reported deaths attributable to respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in young children are important. Recent developments have been noted in the prevention of pneumoviral infections. Method: In this review, we analyzed

APA, Harvard, Vancouver, ISO, and other styles

10

Etefia, Etefia, and Paul Inyang Etoh. "Malaria Vaccine Development: Challenges and Prospects." Medical and Pharmaceutical Journal 2, no. 1 (2023): 28–42. http://dx.doi.org/10.55940/medphar202225.

Full text

Abstract:

Background: The development of a licensed malaria vaccine has been challenging due to the complex multi-stage life cycle, antigenic variation, and genetic diversity of Plasmodium. Numerous vaccines have been developed for various stages of Plasmodium, including pre-erythrocytic, blood stage, placenta, and transmission-blocking vaccines. However, none of these vaccines are completely effective and have high reactogenicity.Aim: The aim of this review is to examine the challenges and prospects in developing an effective malaria vaccine, with a focus on the development of a multi-stage or multival

APA, Harvard, Vancouver, ISO, and other styles

11

kheirollahpour, Mehdi, Mohsen Mehrabi, Naser Mohammadpour Dounighi, Mohsen Mohammadi, and Alireza Masoudi. "Nanoparticles and Vaccine Development." Pharmaceutical Nanotechnology 8, no. 1 (2020): 6–21. http://dx.doi.org/10.2174/2211738507666191024162042.

Full text

Abstract:

In spite of the progress of conventional vaccines, improvements are required due to concerns about the low immunogenicity of the toxicity, instability, and the need for multiple administrations of the vaccines. To overcome the mentioned problems, nanotechnology has recently been incorporated into vaccine development. Nanotechnology increasingly plays an important role in vaccine development nanocarrier-based delivery systems that offer an opportunity to increase the cellular and humoral immune responses. The use of nanoparticles in vaccine formulations allows not only enhanced immunogenicity a

APA, Harvard, Vancouver, ISO, and other styles

12

Desi Irawati, Adinda, and Hotimah Masdan Salim. "Dengue Vaccine Development at the Dengue virus serotypes." International Islamic Medical Journal 1, no. 1 (2019): 9–15. http://dx.doi.org/10.33086/iimj.v1i1.1360.

Full text

Abstract:

Dengue hemorrhagic fever (DHF) is a disease caused by dengue virus (DENV1-4) and is transmitted by the Aedes aegypti mosquito. However, in 2015, official data from the member countries, WHO reported more than 3.2 million cases, including 10,200 severe dengue cases and 1181 deaths. The protein encoded by the genome of dengue virus. Major structural and non structural proteins making up the genome of dengue. From genomic data several studies found that mechanism of vaccine that can use in dengue virus. Several vaccines was establish in the world for example Live attenuated Vaccine, Chimera Vacci

APA, Harvard, Vancouver, ISO, and other styles

13

Zhang, Yihan. "Development, effectiveness, and future directions of HPV vaccines." Theoretical and Natural Science 67, no. 1 (2024): 17–21. https://doi.org/10.54254/2753-8818/2024.18021.

Full text

Abstract:

Human papillomavirus (HPV) vaccines are vaccines used to prevent sexually transmitted diseases caused by HPV. HPV infection is the leading causation that causing the cervical cancer. Specifically, high-risk-type, for instance, HPV-16 and HPV-18, are also connected with some other cancers. This article summarizes the development mechanism, availability, clinical trials, and problems faced by HPV vaccines. Currently, there were three approved HPV vaccines, including bivalent vaccine, quadrivalent vaccine, and nine-valent vaccine, which can prevent different types of HPV infection. The widely uti

APA, Harvard, Vancouver, ISO, and other styles

14

Gottlieb, Sami L., Ann E. Jerse, Sinead Delany-Moretlwe, Carolyn Deal, and Birgitte K. Giersing. "Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap." Sexual Health 16, no. 5 (2019): 426. http://dx.doi.org/10.1071/sh19060.

Full text

Abstract:

Efforts to develop vaccines against Neisseria gonorrhoeae have become increasingly important, given the rising threat of gonococcal antimicrobial resistance (AMR). Recent data suggest vaccines for gonorrhoea are biologically feasible; in particular, epidemiological evidence shows that vaccines against a closely related pathogen, serogroup B Neisseria meningitidis outer membrane vesicle (OMV) vaccines, may reduce gonorrhoea incidence. Vaccine candidates using several approaches are currently in preclinical development, including meningococcal and gonococcal OMV vaccines, a lipooligosaccharide e

APA, Harvard, Vancouver, ISO, and other styles

15

Lim, Xin-Jie, Suria Junus, Lidwina Edwin-Amir, and Aminah Bee Mohd-Kassim. "Vaccination Refusal in Children under 2 Years of Age in Malaysia 2016-2019." Asian Journal of Medicine and Health 21, no. 6 (2023): 1–13. http://dx.doi.org/10.9734/ajmah/2023/v21i6816.

Full text

Abstract:

Aims: This study will explore the incidence rate of childhood vaccination refusal in Malaysia as well as the reasons for this refusal over a four-year period (2016–2019). Given the complexities and dynamic nature of vaccine refusal, this research is essential for defining the target group, identifying the vaccine types they commonly refuse, and comprehending their vaccination concerns. Study Design: This is a retrospective review study. Methodology: This study used a nationally representative secondary data set from the Malaysian Ministry of Health's Family Health Division for the

APA, Harvard, Vancouver, ISO, and other styles

16

Fang, Yuan. "The Role and Impact of Gene Editing on Vaccine Development." Theoretical and Natural Science 82, no. 1 (2025): 63–69. https://doi.org/10.54254/2753-8818/2025.ka21015.

Full text

Abstract:

The application of gene editing technology in vaccine development has brought new hope for dealing with emerging and reemerging infectious diseases. Currently, gene editing tools, represented by CRISPR/Cas9, have significantly accelerated the vaccine development process and improved the safety and efficacy of vaccines by virtue of their highly efficient and precise operational characteristics. However, gene editing technology still suffers from off-target effects and high costs, and its wide application in vaccine development has yet to be further explored. This paper analyzed the application

APA, Harvard, Vancouver, ISO, and other styles

17

Vergati, Matteo, Chiara Intrivici, Ngar-Yee Huen, Jeffrey Schlom, and Kwong Y. Tsang. "Strategies for Cancer Vaccine Development." Journal of Biomedicine and Biotechnology 2010 (2010): 1–13. http://dx.doi.org/10.1155/2010/596432.

Full text

Abstract:

Treating cancer with vaccines has been a challenging field of investigation since the 1950s. Over the years, the lack of effective active immunotherapies has led to the development of numerous novel strategies. However, the use of therapeutic cancer vaccines may be on the verge of becoming an effective modality. Recent phase II/III clinical trials have achieved hopeful results in terms of overall survival. Yet despite these encouraging successes, in general, very little is known about the basic immunological mechanisms involved in vaccine immunotherapy. Gaining a better understanding of the me

APA, Harvard, Vancouver, ISO, and other styles

18

Etefia, Etefia, and Paul Inyang-Etoh. "MALARIA VACCINE DEVELOPMENT: CHALLENGES AND PROSPECTS." University therapeutic journal 6, no. 1 (2024): 14–25. http://dx.doi.org/10.56871/utj.2024.82.25.002.

Full text

Abstract:

Разработка лицензированных вакцин против малярии являлась сложной задачей из-за многоступенчатого жизненного цикла, антигенной изменчивости и большого генетического разнообразия плазмодия, что создавало проблему подбора подходящего кандидата на вакцину среди тысяч антигенов плазмодия. Разработано несколько вакцин для различных стадий плазмодия, которые включают вакцину на предэритроцитарной стадии, вакцины на стадии крови с использованием белков плазмодия, вакцины из плаценты и вакцины, блокирующие передачу инфекции (TBV), которые подавляют половую стадию развития малярийных паразитов. Однако

APA, Harvard, Vancouver, ISO, and other styles

19

Yagovkin, E. A., G. G. Onishchenko, A. Yu Popova, et al. "Condition and Prospects of Development of Vaccines for Specific Prevention of Enterovirus (Nonpolio) Infection." Epidemiology and Vaccine Prevention 15, no. 4 (2016): 74–82. http://dx.doi.org/10.31631/2073-3046-2016-15-4-74-82.

Full text

Abstract:

This review summarizes the material on the development of vaccines against (nonpolio) enterovirus infection in Russia and abroad. Described the developed vaccine types, their characteristics and the results of clinical and epidemiological trials, created in China inactivated vaccines. I’is considered the possibility of creating a mucosal vaccines and vaccinal prevention strategies.

APA, Harvard, Vancouver, ISO, and other styles

20

Voss, Gerald, Danilo Casimiro, Olivier Neyrolles, et al. "Progress and challenges in TB vaccine development." F1000Research 7 (February 16, 2018): 199. http://dx.doi.org/10.12688/f1000research.13588.1.

Full text

Abstract:

The Bacille Calmette Guerin (BCG) vaccine can provide decades of protection against tuberculosis (TB) disease, and although imperfect, BCG is proof that vaccine mediated protection against TB is a possibility. A new TB vaccine is, therefore, an inevitability; the question is how long will it take us to get there? We have made substantial progress in the development of vaccine platforms, in the identification of antigens and of immune correlates of risk of TB disease. We have also standardized animal models to enable head-to-head comparison and selection of candidate TB vaccines for further dev

APA, Harvard, Vancouver, ISO, and other styles

21

Mahesh, Kumar Yadav1 Ankit Kumar Srivastava2 Madhu Vishwakarma2 Juveriya Javed2 Manu Kumar2 Nitu Singh2 Sudhanshu Shekhar2 Gagan Gaykwad2 Faizan Ansari2 Sonu Kumar2 Anchal Kumari2 Deepika Kumari2 Shyam Narayan2 Ramesh Kumar2 Naba Gorai2 Ankita Singh3 Arnab Roy*4 Meghna Singh5. "Comparative Analysis of Immunological Responses and Molecular Mechanisms In SARS-Cov-2 Vaccine Development: Insights from Covishield And Covaxin." International Journal of Scientific Research and Technology 2, no. 5 (2025): 556–83. https://doi.org/10.5281/zenodo.15518160.

Full text

Abstract:

The unprecedented global COVID-19 pandemic catalyzed an extraordinary scientific endeavor in vaccine development, with India emerging as a pivotal contributor through two innovative vaccine platforms: Covishield and Covaxin. These vaccines represent sophisticated molecular engineering strategies addressing the urgent need for effective SARS-CoV-2 intervention mechanisms. Covishield, utilizing a chimpanzee adenoviral vector (ChAdOx1), exemplifies advanced viral vector technology, strategically delivering the spike protein genetic sequence to induce robust immunological responses. The vaccine's

APA, Harvard, Vancouver, ISO, and other styles

22

Mahmoud, Singer, Elsayed Ahmed M, and Husseiny Mohamed I. "Progress in the development of vaccines for pancreatic adenocarcinoma." Annals of Pancreatic Disorders and Treatment 6, no. 1 (2024): 001–5. http://dx.doi.org/10.17352/apdt.000011.

Full text

Abstract:

Pancreatic cancer, which is regarded as the third deadliest cancer globally, poses a significant challenge because of its limited range of treatment options and high mortality rate. Currently, there is a focus on both the development of a novel concept in vaccine designing and the parallel study of the associated immune mechanisms. To further our understanding of the healthcare field, a variety of promising designs have been introduced for in-depth study. The designs were developed to include the mKRAS-specific amphiphile vaccine, which targets a specific mutation in the KRAS gene in addition

APA, Harvard, Vancouver, ISO, and other styles

23

Siagian, Ria Christine, and Jorge Emilio Osorio. "Novel approaches to vaccine development in lower-middle income countries." International Journal of Health Governance 23, no. 4 (2018): 288–300. http://dx.doi.org/10.1108/ijhg-03-2018-0011.

Full text

Abstract:

PurposeThe purpose of this paper is to identify, analyze and describe the novel approaches that affect vaccine development in lower-middle income countries (LMICs).Design/methodology/approachThe vaccine market in LMICs currently focuses on traditional Expanded Program for Immunization vaccines instead of new ones. Unlike the successful introduction of those traditional vaccines, the introduction of new vaccines appears to be very slow, mainly due to financial issues. This paper systematically reviews a set of published papers on vaccine development and analyzes them against a specific region-s

APA, Harvard, Vancouver, ISO, and other styles

24

Dutta, Sudip Kumar, and Thomas Langenburg. "A Perspective on Current Flavivirus Vaccine Development: A Brief Review." Viruses 15, no. 4 (2023): 860. http://dx.doi.org/10.3390/v15040860.

Full text

Abstract:

The flavivirus genus contains several clinically important pathogens that account for tremendous global suffering. Primarily transmitted by mosquitos or ticks, these viruses can cause severe and potentially fatal diseases ranging from hemorrhagic fevers to encephalitis. The extensive global burden is predominantly caused by six flaviviruses: dengue, Zika, West Nile, yellow fever, Japanese encephalitis and tick-borne encephalitis. Several vaccines have been developed, and many more are currently being tested in clinical trials. However, flavivirus vaccine development is still confronted with ma

APA, Harvard, Vancouver, ISO, and other styles

25

Aziz-Andersen, Kaiser Jay. "Vaccinology: Design, Development and Approvals." Journal of Drug Delivery and Therapeutics 12, no. 2 (2022): 156–59. http://dx.doi.org/10.22270/jddt.v12i2.5349.

Full text

Abstract:

The goal of vaccine design and development is to manufacture and consistently produce a vaccine that is safe and effective. The vaccine discovery starts with design input in terms of identification of etiologic agent, immunogenicity, adjuvant, basic scientific concepts, non-clinical and clinical studies, and finally vaccine licensure (FDA approvals). The administering regimens are studied in clinical research laboratory and study materials are tested in suitable bench testing and biological models projecting vaccine candidate’s prophylactic immune response that is safe and effective. The vacci

APA, Harvard, Vancouver, ISO, and other styles

26

D’Amico, Carmine, Flavia Fontana, Ruoyu Cheng, and Hélder A. Santos. "Development of vaccine formulations: past, present, and future." Drug Delivery and Translational Research 11, no. 2 (2021): 353–72. http://dx.doi.org/10.1007/s13346-021-00924-7.

Full text

Abstract:

AbstractThe current situation, heavily influenced by the ongoing pandemic, puts vaccines back into the spotlight. However, the conventional and traditional vaccines present disadvantages, particularly related to immunogenicity, stability, and storage of the final product. Often, such products require the maintenance of a “cold chain,” impacting the costs, the availability, and the distribution of vaccines. Here, after a recall of the mode of action of vaccines and the types of vaccines currently available, we analyze the past, present, and future of vaccine formulation. The past focuses on con

APA, Harvard, Vancouver, ISO, and other styles

27

Gupta, Ayushi, Trilochan Satapathy, Bharti Pradhan, et al. "Experimental Animal Models for Influenza/Flu Virus Vaccine Development." Journal of Drug Delivery and Therapeutics 14, no. 2 (2024): 192–204. http://dx.doi.org/10.22270/jddt.v14i2.6362.

Full text

Abstract:

Objectives: The objective of this review is to explore the different animal models used in the development of Influenza / Flu Virus Vaccine as well as some important guidelines adhered to it. Methods: Laboratory animal models are widely used in the preclinical evaluation of potential vaccines and antiviral compounds to investigate the safety and efficacy of the vaccine or compound in preventing or moderating infection, disease, or secondary transmission. Animal models must also represent humans in terms of similarity of clinical signs, histopathological changes, virus growth kinetics, or

APA, Harvard, Vancouver, ISO, and other styles

28

Iyasu Angani, Dereja. "Veterinary vaccine development: The helical project." Insights in Veterinary Science 4, no. 1 (2020): 042–47. http://dx.doi.org/10.29328/journal.ivs.1001025.

Full text

Abstract:

Vaccine production process have been fuzzy journey to the public and, in some degrees, to those in the setting. By clearly showing the lengthy and challenging journey of vaccine development process, thereby suggesting the economic and health implication of improper use of veterinary vaccines, the paper tries to add the attention given to infection prevention. Starting from the foundations, the types and requirements of veterinary vaccines are described. The paper concludes with current research and regulatory quos in the topic.

APA, Harvard, Vancouver, ISO, and other styles

29

Surendran, Yocyny, Mahalingam Nandikha, Syafinaz Amin-Nordin, Sandeep Kumar Dhanda, Mohamad Ridhuan Mohd Ali, and Narcisse MS Joseph. "Vaccine development for leptospirosis: A systematic review." Asian Pacific Journal of Tropical Medicine 16, no. 12 (2023): 533–45. http://dx.doi.org/10.4103/1995-7645.391775.

Full text

Abstract:

Objective: To assess the efficacy of various types of vaccines developed for leptospirosis. Methods: A comprehensive search was conducted in three databases: PubMed, Scopus, and Cochrane Library. Two authors (YS and MN) selected the articles based on manual screening. The study eligibility criteria are all Leptospira species regardless of any cluster (pathogenic, intermediate and non-pathogenic). This study recorded articles with positive and negative results and showed a comparison among various membrane proteins as vaccine candidates. The studies on the effectiveness of outer membrane protei

APA, Harvard, Vancouver, ISO, and other styles

30

Castanha, Priscila M. S., and Ernesto T. A. Marques. "A Glimmer of Hope: Recent Updates and Future Challenges in Zika Vaccine Development." Viruses 12, no. 12 (2020): 1371. http://dx.doi.org/10.3390/v12121371.

Full text

Abstract:

The emergence and rapid spread of Zika virus (ZIKV) on a global scale as well as the establishment of a causal link between Zika infection and congenital syndrome and neurological disorders triggered unprecedented efforts towards the development of a safe and effective Zika vaccine. Multiple vaccine platforms, including purified inactivated virus, nucleic acid vaccines, live-attenuated vaccines, and viral-vectored vaccines, have advanced to human clinical trials. In this review, we discuss the recent advances in the field of Zika vaccine development and the challenges for future clinical effic

APA, Harvard, Vancouver, ISO, and other styles

31

Yoshikawa, Tomoki. "Vaccine Development for Severe Fever with Thrombocytopenia Syndrome." Viruses 13, no. 4 (2021): 627. http://dx.doi.org/10.3390/v13040627.

Full text

Abstract:

Severe fever with thrombocytopenia syndrome (SFTS), which is caused by SFTS virus (SFTSV), is a tick-borne emerging zoonosis with a high case-fatality rate. At present, there is no approved SFTS vaccine, although the development of a vaccine would be one of the best strategies for preventing SFTS. This article focused on studies aimed at establishing small animal models of SFTS that are indispensable for evaluating vaccine candidates, developing these vaccine candidates, and establishing more practical animal models for evaluation. Innate immune-deficient mouse models, a hamster model, an immu

APA, Harvard, Vancouver, ISO, and other styles

32

Grohmann, Gary. "Regulatory issues in pandemic influenza vaccine development." Microbiology Australia 27, no. 4 (2006): 172. http://dx.doi.org/10.1071/ma06172.

Full text

Abstract:

The Therapeutic Goods Administration (TGA) is responsible for the licensing of vaccines used in Australia. This includes pre-market evaluation aspects (such as assessing the quality, efficacy and safety of vaccines) and post-market aspects (such as batch release testing and the monitoring of adverse reactions). For inter-pandemic and pandemic influenza vaccines, TGA is also involved in the selection of appropriate vaccine viruses and the calibration and supply of reagents for the production of influenza vaccines. Together with industry, TGA has a responsibility to ensure that all regulatory an

APA, Harvard, Vancouver, ISO, and other styles

33

Akiro F., Tugonza. "Innovations in Vaccine Development against Malaria: Prospects for East Africa." INOSR SCIENTIFIC RESEARCH 12, no. 1 (2025): 6–11. https://doi.org/10.59298/inosrsr/2025/12.1.61100.

Full text

Abstract:

Malaria remains a significant public health challenge in East Africa, disproportionately affecting vulnerable populations such as children under five and pregnant women. Despite advancements in vector control, diagnostic tools, and antimalarial therapies, the region faces persistent challenges, including insecticide and drug resistance, logistical barriers, and asymptomatic carriers. Vaccines represent a promising solution to complement existing interventions and disrupt the malaria transmission cycle. This review explores recent innovations in malaria vaccine development, including the RTS,S/

APA, Harvard, Vancouver, ISO, and other styles

34

MORRISON, W. I., and D. J. McKEEVER. "Current status of vaccine development againstTheileriaparasites." Parasitology 133, S2 (2006): S169—S187. http://dx.doi.org/10.1017/s0031182006001867.

Full text

Abstract:

The tick-borne protozoan parasitesTheileria parvaandTheileria annulatacause economically important diseases of cattle in tropical and sub-tropical regions. Because of shortcomings in disease control measures based on therapy and tick control, there is a demand for effective vaccines against these diseases. Vaccines using live parasites have been available for over two decades, but despite their undoubted efficacy they have not been used on a large scale. Lack of infrastructure for vaccine production and distribution, as well as concerns about the introduction of vaccine parasite strains into l

APA, Harvard, Vancouver, ISO, and other styles

35

SHEARER, ADRIENNE E. H., and KALMIA E. KNIEL. "High Hydrostatic Pressure for Development of Vaccines." Journal of Food Protection 72, no. 7 (2009): 1500–1508. http://dx.doi.org/10.4315/0362-028x-72.7.1500.

Full text

Abstract:

Disease management in the food industry is complex and includes use of good hygienic practices, antimicrobials, and immunization. Vaccines are available against many, but not all, disease agents affecting animals reared for human food. Fewer vaccines are currently licensed and widely available for human foodborne pathogens. Increased resistance to antimicrobials provides additional impetus to develop new vaccines. In addition to the need for new vaccines, new methods of vaccine production are desired. Some current methods of vaccine production can involve use of hazardous chemicals, provide in

APA, Harvard, Vancouver, ISO, and other styles

36

Junaidi, Katerine, Dewi Wahyu Fitrina, Fenty Anggrainy, and Deddy Herman. "Overview of COVID-19 Vaccine Development Strategy." Bioscientia Medicina : Journal of Biomedicine and Translational Research 6, no. 3 (2022): 1537–59. http://dx.doi.org/10.37275/bsm.v6i3.473.

Full text

Abstract:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of coronavirus disease 20019 (COVID19) pandemic which first emerged in December 2019 in Wuhan city, China. Currently, a vaccine is urgently needed to control the COVID-19 pandemic. Several vaccine candidates are under development and some are in the final stage of clinical trials. The COVID-19 vaccination aims to reduce morbidity and mortality rates, achieve herd immunity to prevent and protect the society, strengthen the health system, maintain productivity and minimize social and economic impacts. Before

APA, Harvard, Vancouver, ISO, and other styles

37

Mbatha, Londiwe Simphiwe, Jude Akinyelu, Fiona Maiyo, and Tukayi Kudanga. "Future prospects in mRNA vaccine development." Biomedical Materials 18, no. 5 (2023): 052006. http://dx.doi.org/10.1088/1748-605x/aceceb.

Full text

Abstract:

Abstract The recent advancements in messenger ribonucleic acid (mRNA) vaccine development have vastly enhanced their use as alternatives to conventional vaccines in the prevention of various infectious diseases and treatment of several types of cancers. This is mainly due to their remarkable ability to stimulate specific immune responses with minimal clinical side effects. This review gives a detailed overview of mRNA vaccines currently in use or at various stages of development, the recent advancements in mRNA vaccine development, and the challenges encountered in their development. Future pe

APA, Harvard, Vancouver, ISO, and other styles

38

Zhao, Ziyao, Sahra Bashiri, Zyta M. Ziora, Istvan Toth, and Mariusz Skwarczynski. "COVID-19 Variants and Vaccine Development." Viruses 16, no. 5 (2024): 757. http://dx.doi.org/10.3390/v16050757.

Full text

Abstract:

Coronavirus disease 2019 (COVID-19), the global pandemic caused by severe acute respiratory syndrome 2 virus (SARS-CoV-2) infection, has caused millions of infections and fatalities worldwide. Extensive SARS-CoV-2 research has been conducted to develop therapeutic drugs and prophylactic vaccines, and even though some drugs have been approved to treat SARS-CoV-2 infection, treatment efficacy remains limited. Therefore, preventive vaccination has been implemented on a global scale and represents the primary approach to combat the COVID-19 pandemic. Approved vaccines vary in composition, although

APA, Harvard, Vancouver, ISO, and other styles

39

Chow, Stephanie, Jonathan S. Berek, and Oliver Dorigo. "Development of Therapeutic Vaccines for Ovarian Cancer." Vaccines 8, no. 4 (2020): 657. http://dx.doi.org/10.3390/vaccines8040657.

Full text

Abstract:

Ovarian cancer remains the deadliest of all gynecologic malignancies. Our expanding knowledge of ovarian cancer immunology has allowed the development of therapies that generate systemic anti-tumor immune responses. Current immunotherapeutic strategies include immune checkpoint blockade, cellular therapies, and cancer vaccines. Vaccine-based therapies are designed to induce both adaptive and innate immune responses directed against ovarian cancer associated antigens. Tumor-specific effector cells, in particular cytotoxic T cells, are activated to recognize and eliminate ovarian cancer cells. V

APA, Harvard, Vancouver, ISO, and other styles

40

Abdelkhalek, Ahmed F., and Janet M. Daly. "The Value of a Comparative Approach with Equine Vaccine Development for the Development of Human Influenza DNA Vaccines." Zoonotic Diseases 4, no. 4 (2024): 245–58. http://dx.doi.org/10.3390/zoonoticdis4040021.

Full text

Abstract:

A comparative medicine approach, whereby similarities and differences in biology between human and veterinary species are used to enhance understanding for the benefit of both, is highly relevant to the development of viral vaccines. Human and equine influenza share many similarities in pathogenesis and immune responses. The DNA vaccine approach offers potential advantages for responding rapidly and effectively to outbreaks or pandemics in both humans and animals, especially in under-resourced regions. The European and American vaccine regulatory authorities require demonstration of vaccine ef

APA, Harvard, Vancouver, ISO, and other styles

41

Knowles, Jamie, Jacob Lohr, and J. Yarnall. "Development of Vaccine Preferences among Parents of Newborns." Journal of Pediatric Infectious Diseases 13, no. 03 (2018): 169–77. http://dx.doi.org/10.1055/s-0037-1620266.

Full text

Abstract:

Objective Vaccine hesitancy and refusal and the resulting outbreaks of vaccine-preventable diseases continue to be an issue today. Most of contemporary research on these issues has focused on underlying characteristics of non-vaccinators and ambivalent parents; however, few studies have looked into how or when vaccine preferences develop. In this study, we sought to explore when parental preferences for vaccines develop in relation to a pregnancy. We also examined self-reported influences on vaccine decision making. Methods We recruited and administered a short survey to parents at the North C

APA, Harvard, Vancouver, ISO, and other styles

42

Romano, Maria, Flavia Squeglia, Eliza Kramarska, et al. "A Structural View at Vaccine Development against M. tuberculosis." Cells 12, no. 2 (2023): 317. http://dx.doi.org/10.3390/cells12020317.

Full text

Abstract:

Tuberculosis (TB) is still the leading global cause of death from an infectious bacterial agent. Limiting tuberculosis epidemic spread is therefore an urgent global public health priority. As stated by the WHO, to stop the spread of the disease we need a new vaccine, with better coverage than the current Mycobacterium bovis BCG vaccine. This vaccine was first used in 1921 and, since then, there are still no new licensed tuberculosis vaccines. However, there is extremely active research in the field, with a steep acceleration in the past decades, due to the advance of technologies and more rati

APA, Harvard, Vancouver, ISO, and other styles

43

Bayan Khalid Baabdullah. "The Role of Pharmacology in Vaccine Development." Power System Technology 48, no. 4 (2024): 4869–902. https://doi.org/10.52783/pst.1313.

Full text

Abstract:

Pharmacology plays a vital role in the development, optimization, and efficacy of vaccines. As the study of how drugs interact with biological systems, pharmacology offers the foundational knowledge necessary to design vaccines that stimulate the immune system effectively without causing undue harm to the individual. The pharmaceutical and biotechnological industries rely heavily on pharmacological principles to ensure that vaccines are not only safe but also potent and long-lasting. From understanding antigen-antibody interactions to optimizing adjuvants and delivery mechanisms, pharmacology

APA, Harvard, Vancouver, ISO, and other styles

44

Kong, Dechuan, Hao Pan, Huanyu Wu, and Jian Chen. "Engaging Broader Stakeholders to Accelerate Group A Streptococcus Vaccine Development." Vaccines 13, no. 7 (2025): 734. https://doi.org/10.3390/vaccines13070734.

Full text

Abstract:

Group A Streptococcus (GAS) imposes a significant global health burden across all age groups, annually causing over 600 million cases of pharyngitis and more than 18 million severe invasive infections or sequelae. The resurgence of scarlet fever globally and streptococcal toxic shock syndrome (STSS) outbreaks in Japan have brought GAS infections back into the spotlight as a pressing global health concern. Unfortunately, no licensed vaccine against GAS is yet available for clinical use. Our comprehensive review examines the developmental history of GAS vaccines, outlining the research trajector

APA, Harvard, Vancouver, ISO, and other styles

45

R, Fatima, Bilolikar AK, Reddy SG, and Banerjee J. "An integrative review on development of COVID vaccine." Journal of Medical and Scientific Research 8, S1 (2020): 117–23. http://dx.doi.org/10.17727/jmsr.2020/8s1-15.

Full text

Abstract:

The world is in dire need of safe, effective coronavirus disease 2019 (COVID-19) vaccine strategies. Since its emergence in November 2019, it has spread to 188 countries and 25 territories around the globe, despite elaborate efforts by World Health Organization (WHO) and governments to contain the infection, primarily owing to the highly infectious nature of this virus. Present article reviews various aspects in process of vaccine designing, vaccine platforms and current efforts and progress of COVID-19 vaccine candidates. The founding of the COVID-19 vaccines global access (COVAX) facility by

APA, Harvard, Vancouver, ISO, and other styles

46

Khan, Fazal Mehmood. "Bacteriophage-based Vaccine: A New Dawn for Vaccine Design and Development." Proceedings of the Pakistan Academy of Sciences: B. Life and Environmental Sciences 60, S (2023): 107–14. http://dx.doi.org/10.53560/ppasb(60-sp1)835.

Full text

Abstract:

The COVID-19 epidemic has strained healthcare systems, causing stress among personnel and facing significant economic and social issues. COVID-19 patients have significant symptoms, necessitating prompt treatment. It is a global urgency to develop effective vaccinations against COVID-19. Quick immunization of the whole world population against an ever-changing, extremely deadly virus is alarming, and various vaccine techniques are being researched. Bacteriophages are helpful in the treatment of multidrug-resistant bacterial infections. But, their clinical efficacy may go far beyond. One of the

APA, Harvard, Vancouver, ISO, and other styles

47

Mason, Andrew N., and Ahmed Elkassabgi. "Evidence of Abnormal Trading on COVID-19 Pfizer Vaccine Development Information." Journal of Risk and Financial Management 15, no. 7 (2022): 299. http://dx.doi.org/10.3390/jrfm15070299.

Full text

Abstract:

The 2019 COVID-19 pandemic led to an economic slowdown worldwide and shook the investment world. Pharmaceutical investments were influenced by the anticipation of COVID-19 vaccine developments. Our study examines the real-time impact of public announcements concerning COVID-19 vaccine developments on stock returns and volatilities for Pfizer, Moderna, and the S&P 500. Market Return and Information Event methodology were used to analyze stock activities immediately before important public COVID-19 vaccine development announcements related to Pfizer and Moderna vaccines. This methodology was

APA, Harvard, Vancouver, ISO, and other styles

48

Jones, T. R., and S. L. Hoffman. "Malaria vaccine development." Clinical Microbiology Reviews 7, no. 3 (1994): 303–10. http://dx.doi.org/10.1128/cmr.7.3.303.

Full text

Abstract:

The malaria parasite life cycle presents several targets for attack, but these different parts of the life cycle are susceptible to different types of host immune response. For example, the sporozoite is most sensitive to immune antibody, while liver stage parasites can be eliminated by cytotoxic T lymphocytes. Attachment of merozoites to erythrocytes, on the other hand, can be blocked by antibody. Convincing experimental evidence shows that completely protective immunity to malaria can be induced. The challenge now is to design recombinant or synthetic vaccines that induce the right types of

APA, Harvard, Vancouver, ISO, and other styles

49

Tiwari, Kunal, Rahul Saxena, and Dr Sarika Saxena. "MOLECULAR TECHNIQUES ADOPTED AGAINST SARS-COV-2 IN VACCINE DEVELOPMENT." International Journal of Engineering Applied Sciences and Technology 6, no. 6 (2021): 197–206. http://dx.doi.org/10.33564/ijeast.2021.v06i06.028.

Full text

Abstract:

In this review, we attempted to highlight the uniqueness and difference among vaccines. Vaccine is a biological preparation that improves immunity to diseases and protect us from Covid 19. The term vaccine applies to all biological preparations produced by the living organisms, that enhance immunity against disease and the techniques used for the development of vaccines were reverse vaccinology, structural vaccinology, synthetic biology, and vaccine adjuvants. Besides these mRNA vaccines, we will also highlight the Protein subunit vaccines, which include separated proteins from viral or bacter

APA, Harvard, Vancouver, ISO, and other styles

50

Schrager, Lewis K., Rebecca C. Harris, and Johan Vekemans. "Research and development of new tuberculosis vaccines: a review." F1000Research 7 (November 1, 2018): 1732. http://dx.doi.org/10.12688/f1000research.16521.1.

Full text

Abstract:

Tuberculosis kills more people worldwide than any other single infectious disease agent, a threat made more dire by the spread of drug-resistant strains ofMycobacterium tuberculosis (Mtb). Development of new vaccines capable of preventing TB disease and newMtbinfection are an essential component of the strategy to combat the TB epidemic. Accordingly, the WHO considers the development of new TB vaccines a major public health priority. In October 2017, the WHO convened a consultation with global leaders in the TB vaccine development field to emphasize the WHO commitment to this effort and to fac

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!